Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS

Lancet

Volumn 363, Issue 9427, 2004, Pages 2122-2127

  Bukreyev, Alexander ^a   Lamirande, Elaine W ^a   Buchholz, Ursula J ^a   Vogel, Leatrice N ^a   Elkins, William R ^a   St Claire, Marisa ^b   Murphy, Brian R ^a   Subbarao, Kanta ^a   Collins, Peter L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BIOQUAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; CERCOPITHECUS; CONTROLLED STUDY; CORONAVIRUS; FEMALE; INFECTION PREVENTION; MALE; MUCOSAL IMMUNITY; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE DRUG DOSE; VIRUS RECOMBINANT; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 3042557960     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16501-X     Document Type: Article

References (29)

1. WHO. Communicable disease surveillence and response: severe acute respiratory syndrome (SARS) http://www.who.int/csr/sars/en. (accessed Dec 31, 2003).
2. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 348:2003;1953-1966
3. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 348:2003;1995-2005
4. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 348:2003;1967-1976
5. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 300:2003;1394-1399
6. Zeng FY, Chan CW, Chan MN, et al. The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39). Exp Biol Med (Maywood). 228:2003;866-873
7. The complete genome of the SARS associated Coronavirus. Gene Bank sequence AY274119 2003.
8. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 362:2003;263-270
9. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. 349:2003;2431-2441
10. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 361:2003;1767-1772
11. Schmidt A, McAuliffe J, Huang A, et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol. 74:2000;8922-8929
12. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol. 2001:2001;4594-4603
13. Durbin AP, Skiadopoulos MH, McAuliffe JM, Riggs JM, Surman SR, Collins PL, Murphy BR. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol. 74:2000;6821-6831
14. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest. 110:2002;21-27
15. Tang RS, Schickli JH, MacPhail M, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol. 77:2003;10819-10828
16. Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J. 15:1996;650-654
17. Callebaut P, Pensaert M. Expression and immunogenicity of the spike glycoprotein of porcine respiratory coronavirus encoded in the E3 region of adenovirus. Adv Exp Med Biol. 380:1995;265-270
18. Daniel C, Talbot PJ. Protection from lethal coronavirus infection by affinity-purified spike glycoprotein of murine hepatitis virus, strain A59. Virology. 174:1990;87-94
19. Tuboly T, Nagy E, Dennis JR, Derbyshire JB. Immunogenicity of the S protein of transmissible gastroenteritis virus expressed in baculovirus. Arch Virol. 137:1994;55-67
20. Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol. 78:2004;3572-3577
21. Kolakofsky D, Pelet T, Garcin D, Hausmann S, Curran J, Roux L. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol. 72:1998;891-899
22. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 11:1993;1395-1404
23. Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis. 4:1981;175-189
24. Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 423:2003;240
25. Martina BE, Haagmans BL, Kuiken T, et al. Virology: SARS virus infection of cats and ferrets. Nature. 425:2003;915
26. Clements ML, Belshe RB, King J, et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol. 29:1991;1175-1182
27. Karron RA, Wright PF, Newman FK, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis. 172:1995;1445-1450
28. Tao T, Skiadopoulos MH, Davoodi F, Riggs JM, Collins PL, Murphy BR. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J Virol. 74:2000;6448-6458
29. Tao T, Durbin AP, Whitehead SS, Davoodi F, Collins PL, Murphy BR. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol. 72:1998;2955-2961